Loading clinical trials...
Loading clinical trials...
Case-control Study Evaluating the Impact of p16Ink4a in Bronchopulmonary Dysplasia in Children
The bronchopulmonary dysplasia (BPD) is a respiratory disease of the premature child which lead to a reduction of gas exchange surface and to a prolonged respiratory failure. This disease has morphologic and functional consequences at adulthood and is today considered to be an early determinant of respiratory diseases at adulthood. The physiopathology of BPD is not well known. Several mechanisms could be involved especially a reparation failure favored by an increase of cellular senescence which is a permanent stop of cellular proliferation. The transcription factor 16 Ink4a, considered as a marker of aging, is one of the essential markers of senescence. Its increase during prematurity was shown at the blood cells of the cordon, but its involvement in BPD and its evolution in child are not yet studied.
Age
0 - 15 years
Sex
ALL
Healthy Volunteers
No
Centre Hospitalier Intercommunal de Créteil
Créteil, France
Start Date
March 7, 2018
Primary Completion Date
March 7, 2022
Completion Date
December 30, 2023
Last Updated
June 7, 2023
80
ACTUAL participants
Blood punction
OTHER
Lead Sponsor
Centre Hospitalier Intercommunal Creteil
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06342752